Biomerica Inc. , a global leader in innovative medical diagnostics, proudly announces a landmark multi-year exclusive distribution agreement with one of the United Arab Emirates' foremost healthcare conglomerates. This strategic partnership marks a significant step forward in advancing the accessibility and efficacy of colorectal cancer screening and breast examination technologies across the region.

Strategic Partnership Highlights:

Biomerica has entered into a multi-year agreement with a UAE-based multi-billion dollar healthcare powerhouse, securing a substantial initial order for the Company’s at-home screening products, EZ Detect™ and Aware®. This collaboration aims not only to bolster the distribution of these cutting-edge health screening tools throughout the UAE but also to collaborate with governmental health departments to integrate these tests into national health protocols.

The partnership underscores a mutual commitment between Biomerica and its UAE partner to alleviate the burden of cancer through early detection and innovative healthcare solutions. Together, the companies are exploring avenues to introduce additional Biomerica products to the UAE, further enhancing their impact on healthcare advancement in the region.

EZ Detect™: Colorectal Screening Made Simple:

EZ Detect™ emerges as the most user-friendly at-home screening test for colorectal diseases available on the market today. This FDA-cleared test detects occult (hidden) blood in stool, an early indicator of colorectal cancer. Designed with convenience in mind, EZ Detect™ eliminates the need for cumbersome stool handling, providing a discreet and swift screening experience directly in the comfort of one’s home. With a straightforward process that involves dropping the test pad into the toilet, observing a color change, and flushing, EZ Detect™ significantly reduces barriers to regular screening, driving increased adoption rates and facilitating early detection efforts. The recent approval of insurance reimbursement for EZ Detect™ by the Dubai Health Authority further underscores its significance in public health and enhances its affordability and accessibility.

Aware®: Pioneering Breast Health Self-Exams:

Aware® represents a groundbreaking, FDA-cleared device that heightens tactile sensitivity during breast self-examinations. By enabling women to detect changes in breast tissue more easily, Aware® plays a pivotal role in early breast cancer detection. With over 70% of diagnosed cases lacking a family history of breast cancer, tools like Aware® significantly improve the likelihood of successful treatment.

Broader Health Impact and Company Commitment:

Zack Irani, CEO of Biomerica, expressed his enthusiasm for the partnership, stating, "This collaboration signifies a significant stride forward in our commitment to screening. By joining forces with one of the UAE’s premier healthcare companies, we are not only distributing products but also advocating for a paradigm shift towards proactive health management in the Middle East. The inclusion of EZ Detect™ in insurance coverage by the Dubai government is a testament to this shift and sets the stage for greater health security. We are working tirelessly to achieve similar milestones with the Aware product."